KSQ Therapeutics Competitors, Revenue and Alternatives

Claim your profile

Overview

Location:
Boston, MA USA
Total Funding:$156.6M
Industry:Pharma
Founded:2015
Lead Investor(s):N/A
Press
Claim your profile

City Ranking

Industry Ranking

State Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • KSQ Therapeutics's estimated annual revenue is currently $11.5M per year.
  • KSQ Therapeutics received $80.0M in venture funding in October 2018.
  • KSQ Therapeutics's estimated revenue per employee is $201,000
  • KSQ Therapeutics's total funding is $156.6M.

Employee Data

  • KSQ Therapeutics has 57 Employees.
  • KSQ Therapeutics grew their employee count by -38% last year.
  • KSQ Therapeutics currently has 1 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
Ironwood Pharma...
N/A445N/AN/A
Infinity Pharma...
N/A411N/AN/A
Kala Pharmaceut...
$10.7M1521%N/A
Karyopharm Ther...
$30.3M38550%N/A
Carna Bioscienc...
$5.4M27N/AN/A
PRECISIONadviso...
$11.5M5736%N/A
Boston Pharmace...
$17.3M8648%N/A
Vita Data Scien...
$10.3M5150%N/A
Veristat
$38M25815%N/A
Radius Health
N/A453N/AN/A
Missing a competitor? Contribute!?
Submit

KSQ Therapeutics has built an industry-leading genome-scale precision functional genomics platform, called CRISPRomics, to pinpoint therapeutic nodes that directly correlate genomic function to disease with unprecedented certainty and speed. The company is deploying CRISPRomics for novel drug development across broad therapeutic areas and is currently advancing a proprietary pipeline of tumor- and immune-focused drug candidates. KSQ was founded by thought leaders in the field of functional genomics and pioneers of CRISPR screening technologies, and the company is located in Cambridge, Massachusetts. For more information, please visit the company's website at www.ksqtx.com.

keywords:N/A

57

Number of Employees

$11.5M

Revenue (est)

1

Current Jobs

-38%

Employee Growth %

$156.6M

Total Funding

N/A

Valuation

N/A

Accelerator

N/A

Type

Executive Contacts

NameTitleEmail
Jason MerkinPrincipal Scientist
Caroline DugopolskiVP, Head of Technical Operations
Jeff DavisHead Of Clinical OperationsEmail Available
Beni WolfChief Medical OfficerEmail Available
John ChoPrincipal Scientist
Gregory KryukovSr. Director, Computational BiologyEmail Available
Giovanni CianchettaDirector Computational Chemistry Email Available
Rene LemieuxVice President, Head Of Small Molecule Drug Discovery
Andrew OlaharskiSenior Director And Head Of ToxicologyEmail Available
Louise CadzowSenior director, head of in vivoEmail Available

KSQ Therapeutics News

13-Sep-19 - TIDAL Unplugged, Emerging Artist Program, Announces ...

... (AVIR); Denali Therapeutics (DNLI); Rubius Therapeutics (RUBY); Syros Pharmaceuticals (SYRS); Sana Biotechnology; KSQ Therapeutics; ...

16-Apr-19 - KSQ Therapeutics Announces Appointment of Douglas Pagán ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- KSQ Therapeutics today announced the appointment of Douglas Pagán as Chief Financial Officer.

16-Apr-19 - KSQ Therapeutics Announces Appointment of Beni B. Wolf ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--KSQ Therapeutics today announced the appointment of Beni B. Wolf, MD, PhD, as Chief Medical ...

KSQ Therapeutics Funding

DateAmountRoundLead InvestorsReference
2017-10-03$76.0MUndisclosedMultipleArticle
2018-10-01$80.0MCMultipleArticle